5 Orville Drive, Suite 200
59 articles with Sartorius
At virtual Annual General Shareholders' Meeting, shareholders granted discharge to the Executive Board and the Supervisory Board and approved the boards' proposals by a large majority.
The life science group Sartorius confirmed its preliminary figures for 2020 upon the release of its annual report.
Sartorius closes 2020 with strong growth to well over 2 billion euros and a further increase in profitability
Preliminary results for the full year of 2020: Order intake up 49.0 percent; sales revenue up 30.2 percent; underlying EBITDA margin climbs to 29.6 percent
The life science company Sartorius announced it has entered into an agreement through its subgroup Sartorius Stedim Biotech to acquire the chromatography process equipment division of Novasep.
Sartorius recently recognized startup company MyoGene Bio at the QB3 Pitch Summit, a competition showcasing promising new life science companies. This award provides the company with a $25,000 voucher that they can use for the purchase of any Sartorius products and services to support their development of a gene therapy for Duchenne muscular dystrophy (DMD). MyoGene Bio’s MyoDys 45-55 gene editing therapy uses CRISPR
- Transaction provides a complementary fit with Sartorius' separation portfolio, adding innovative crossflow filtration units for easy-to-use bioprocessing devices - Technology is especially suited to gene and cell therapy applications, vaccine production and intensified bioprocessing
The life science company Sartorius successfully closed the acquisition of the Slovenian purification specialist BIA Separations.
Nine-month results: Order intake1 up 37.8 percent; sales revenue up 25.2 percent; underlying EBITDA1 margin climbs to 29.1 percent
The life science company Sartorius announced it has entered into a definitive agreement to merge purification specialist BIA Separations into its subgroup Sartorius Stedim Biotech in a transaction totaling 360 million euros of which 240 million euros will be paid in cash and 120 million euros in Sartorius Stedim Biotech shares.
Successful first half: Order intake1 up 27.5 percent, Group sales revenue up 17.9 percent, underlying EBITDA1 margin reaches 27.8 percent
Stronger growth and higher profitability expected for the Bioprocess Solutions Division and the entire Group; outlook for the Lab Products & Services Division unchanged
Group sales revenue up 16.5%; order intake up 29.7%; underlying EBITDA margin 27.0%
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for March 31, 2020.
3/26/2020Pharma and life sciences companies from across the globe provide updates on their pipelines and business practices.
Sartorius Supports the Development of the First Vaccine Candidate Against the Novel Coronavirus to Enter Clinical Trials
Sartorius has supported CanSino Biologics Inc. and Maj. Gen. Chen Wei’s team at the Institute of Bioengineering at the Academy of Military Medical Sciences in China in their development of the first vaccine candidate against the novel coronavirus SARS-CoV-2 to enter clinical trials.
A summary of daily biopharma industry news. Please check out stories that are trending on March 25, 2020.
European and U.S. Antitrust Authorities Clear Acquisition of Select Danaher Life Science Businesses by Sartorius Stedim Biotech
On March 18 and March 19, 2020 respectively, the European Commission and the U.S. Federal Trade Commission cleared the proposed acquisition of select Danaher life science businesses by Sartorius, SSB's major shareholder. Both approvals are an important milestone for the transaction originally announced in October 2019 , the co
European and U.S. Antitrust Authorities Clear Acquisition of Select Danaher Life Science Businesses by Sartorius
On March 18 and March 19, 2020 respectively, the European Commission and the U.S. Federal Trade Commission cleared the proposed acquisition of select Danaher businesses by Sartorius. Both approvals are an important milestone for the transaction originally announced in October 2019 , the completion of which is still subject
Sartorius will postpone its Annual General Shareholders' Meeting formerly scheduled for March 26, 2020, to a later date due to the coronavirus pandemic and the associated restrictive rules imposed on meetings.
Sartorius Launches BIOSTAT STR® Generation 3 with BIOBRAIN - Making Biopharmaceutical Development and Production Faster, Simpler and Safer
Engineered to address the rigorous requirements and complexity of biologics manufacture, Sartorius’ BIOSTAT STR® Generation 3 single-use bioreactor and BIOBRAIN automation platform introduce innovations that will change the field of biopharmaceutical process development and manufacturing.